{
  "metadata": {
    "start_time": "2025-06-20T04:54:06.470437",
    "mode": "full",
    "gpu_info": {
      "gpu_count": 1,
      "current_device": 0,
      "gpu_name": "NVIDIA GeForce RTX 4090",
      "gpu_memory_gb": 23.64288330078125,
      "cuda_version": "11.8",
      "platform": "Local"
    },
    "benchmarks": [
      "mirage",
      "medreason",
      "pubmedqa",
      "msmarco"
    ],
    "models": [
      "hierarchical_system"
    ],
    "end_time": "2025-06-20T04:55:13.084617",
    "total_duration_seconds": 66.61418
  },
  "results": {
    "mirage": {
      "benchmark_name": "mirage",
      "start_time": "2025-06-20T04:54:10.387667",
      "models": {
        "hierarchical_system": {
          "results": {
            "model_name": "unknown_model",
            "benchmark_name": "MIRAGE",
            "evaluation_time": 8.333119630813599,
            "total_questions": 5,
            "successful_evaluations": 5,
            "metrics": {
              "total_questions": 5,
              "average_score": 57.28714729547501,
              "accuracy": 20.0,
              "correct_answers": 1,
              "benchmark_name": "MIRAGE"
            },
            "individual_results": [
              {
                "question_id": "mirage_001",
                "question_type": "clinical",
                "score": 82.5,
                "correct": true,
                "metrics": {
                  "semantic_similarity": 0.85,
                  "medical_accuracy": 1.0,
                  "clinical_relevance": 0.5,
                  "overall_score": 0.825
                },
                "response": " Based on the pattern recognition, hypothesis testing, and confirmation performed using comprehensive medical knowledge, evidence-based sources, and detailed clinical reasoning, the first-line treatment for Type 2 Diabetes Mellitus is Metformin. This recommendation is supported by numerous clinical trials such as UKPDS, ADOPT, Cochrane meta-analyses, and ADA/EASD guidelines that demonstrate significant improvements in patient outcomes, including reduced mortality rates and lower cardiovascular risks. The evidence presented includes multiple clinical success stories showing the effectiveness of Metformin-based therapy with lifestyle modification in reducing cardiovascular events and improving glycemic control in patients with Type 2 Diabetes Mellitus and cardiovascular risk.",
                "ground_truth": "Metformin",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "mirage_002",
                "question_type": "clinical",
                "score": 57.51735174655914,
                "correct": false,
                "metrics": {
                  "semantic_similarity": 0.6703470349311829,
                  "medical_accuracy": 0.8,
                  "clinical_relevance": 0.0,
                  "overall_score": 0.5751735174655914
                },
                "response": " The main symptoms of a myocardial infarction (heart attack) include:\n1. Chest pain or discomfort, which can feel like pressure, fullness, squeezing, or aching in the center of the chest and can last for more than a few minutes or go away and come back.\n2. Pain that spreads to your shoulders, neck, jaw, arms, or back.\n3. Shortness of breath, which may occur at rest or during physical exertion.\n4. Cold sweat, nausea, or lightheadedness.\n5. Fatigue or weakness.\n6. Rapid or irregular heartbeat.\n\nIf you suspect that you or someone else is experiencing a heart attack, seek immediate medical attention. Call emergency services right away (in the US: 911).",
                "ground_truth": "chest pain, shortness of breath, nausea, sweating",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "mirage_003",
                "question_type": "clinical",
                "score": 50.999660432338715,
                "correct": false,
                "metrics": {
                  "semantic_similarity": 0.3399932086467743,
                  "medical_accuracy": 0.8,
                  "clinical_relevance": 0.5,
                  "overall_score": 0.5099966043233871
                },
                "response": " The medication Amlodipine, which is a Calcium Channel Blocker, is generally safe to use during pregnancy. However, it's important to note that other medications like ACE inhibitors and Angiotensin II Receptor Antagonists (ARBs) are contraindicated in pregnancy due to the risk of fetal harm. Always consult with a healthcare professional for individual patient care and management.",
                "ground_truth": "ACE inhibitors",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "mirage_004",
                "question_type": "clinical",
                "score": 43.781010150909424,
                "correct": false,
                "metrics": {
                  "semantic_similarity": 0.2956202030181885,
                  "medical_accuracy": 0.8,
                  "clinical_relevance": 0.25,
                  "overall_score": 0.4378101015090942
                },
                "response": " The normal range for HbA1c (also known as glycohemoglobin or glycated hemoglobin) is typically between 4% and 5.6%. In diabetes management, a lower HbA1c level indicates better blood sugar control over the past 2-3 months. However, it's essential to consider individual patient factors, such as age, duration of diabetes, presence of complications, comorbidities, and tolerability to medications when setting target levels. In the context of the provided information, a decrease in HbA1c from 8.2% to 6.8% is considered significant improvement and better blood sugar control.",
                "ground_truth": "less than 7% for most adults",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "mirage_005",
                "question_type": "research",
                "score": 51.63771414756775,
                "correct": false,
                "metrics": {
                  "semantic_similarity": 0.552754282951355,
                  "medical_accuracy": 0.8,
                  "clinical_relevance": 0.0,
                  "overall_score": 0.5163771414756775
                },
                "response": " Statins work by competitively inhibiting HMG-CoA reductase, an enzyme responsible for producing cholesterol in the liver. By doing so, they lower the levels of LDL (low-density lipoprotein) or \"bad\" cholesterol in the bloodstream. Additionally, statins exhibit pleiotropic effects that contribute to their clinical benefits, such as reducing inflammation and promoting endothelial function.",
                "ground_truth": "HMG-CoA reductase inhibition",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              }
            ],
            "status": "completed"
          },
          "evaluation_time_seconds": 8.334989,
          "gpu_stats": {
            "allocated_gb": 0.18,
            "reserved_gb": 0.21,
            "total_gb": 23.64,
            "utilization_percent": 0.7
          }
        }
      },
      "end_time": "2025-06-20T04:54:18.916961"
    },
    "medreason": {
      "benchmark_name": "medreason",
      "start_time": "2025-06-20T04:54:18.918483",
      "models": {
        "hierarchical_system": {
          "results": {
            "model_name": "unknown_model",
            "benchmark_name": "MedReason",
            "evaluation_time": 14.62362551689148,
            "total_questions": 5,
            "successful_evaluations": 5,
            "metrics": {
              "accuracy": 0.0,
              "total_questions": 5,
              "correct_answers": 0,
              "average_score": 34.84416291936148,
              "reasoning_quality": 0.525,
              "clinical_accuracy": 0.1943939393939394,
              "diagnostic_process": 0.22666666666666666,
              "knowledge_integration": 0.3479011404209965,
              "failed_questions": 0,
              "error_rate": 0.0,
              "benchmark_name": "MedReason"
            },
            "individual_results": [
              {
                "question_id": "medreason_001",
                "score": 36.68057553956835,
                "correct": false,
                "metrics": {
                  "reasoning_quality": 0.5083333333333333,
                  "clinical_accuracy": 0.16999999999999998,
                  "diagnostic_process": 0.3733333333333333,
                  "knowledge_integration": 0.3780575539568345,
                  "overall_score": 0.3668057553956835
                },
                "response": " Based on the presented pattern recognition and hypothesis testing, the following hierarchical diagnostic response can be formulated for a 55-year-old patient presenting with chest pain:\n\nTIER 1 - PATTERN RECOGNITION:\nIdentified patterns suggest an Acute Coronary Syndrome (ACS) diagnosis given the patient's age and symptoms. The differential diagnoses include Unstable Angina, Non-ST elevation Myocardial Infarction (NSTEMI), and ST elevation Myocardial Infarction (STEMI).\n\nTIER 2 - HYPOTHESIS TESTING:\nGiven the identified patterns, the following hypotheses were tested using evidence-based reasoning chains:\n\nHypothesis 1: Evidence Base: CURE, TRITON-TIMI, PLATO trials, ESC/AHA guidelines\n\nClinical Recommendation: Dual antiplatelet therapy (Aspirin + P2Y12 inhibitor) is the preferred first-line therapy for ACS based on robust clinical trial evidence demonstrating significant improvements in patient outcomes. The patient should also receive beta blockers and statins as per guidelines.\n\nTIER 3 - CONFIRMATION:\nThe diagnostic confirmation is based on comprehensive clinical evidence synthesis:\n\nEvidence 1: Key Learning Points:\n\u2022 Evidence-based therapy translates to improved patient outcomes\n\u2022 Guideline-recommended treatments provide consistent clinical benefits\n\u2022 Proper implementation of proven therapies is essential for optimal care in ACS\n\nThe systematic diagnostic approach for a 55-year-old patient presenting with chest pain suggests an initial evaluation for ACS, followed by dual antiplatelet therapy (Aspirin + P2Y12 inhibitor), beta blockers, and statins as per guidelines. Further testing such as ECG, troponin levels, and imaging studies may be required to confirm the diagnosis and guide appropriate treatment.",
                "expected": "systematic evaluation including detailed history, physical examination, ECG, cardiac enzymes, chest X-ray",
                "reasoning_type": "diagnostic_approach",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "medreason_002",
                "score": 43.8,
                "correct": false,
                "metrics": {
                  "reasoning_quality": 0.7,
                  "clinical_accuracy": 0.22999999999999998,
                  "diagnostic_process": 0.2533333333333333,
                  "knowledge_integration": 0.3833333333333333,
                  "overall_score": 0.43799999999999994
                },
                "response": " Based on the pattern recognition of clinical guidelines and evidence-based medicine, the preferred first-line therapy for Acute Coronary Syndrome (STEMI), specifically, is Dual antiplatelet therapy (Aspirin + P2Y12 inhibitor). This recommendation is supported by robust clinical trial evidence from the CURE, TRITON-TIMI, PLATO trials, and ESC/AHA guidelines.\n\nThe hierarchical diagnostic reasoning process includes:\n\n1. Pattern Recognition: Identified patterns are recommendations in major international guidelines with Grade A evidence from multiple randomized controlled trials and meta-analyses for the treatment of Acute Coronary Syndrome (STEMI).\n\n2. Hypothesis Testing: The hypothesis tested is that Dual antiplatelet therapy (Aspirin + P2Y12 inhibitor) is the preferred first-line therapy for Acute Coronary Syndrome based on robust clinical trial evidence demonstrating significant improvements in patient outcomes.\n\n3. Confirmation: The diagnosis and recommended treatment are confirmed with comprehensive clinical evidence, including multiple clinical success stories demonstrating successful revascularization, no recurrent events at 1 year, and return to normal activity after administering dual antiplatelet therapy and primary PCI for Acute Coronary Syndrome (STEMI).\n\nIn summary, for a patient with acute ST-elevation myocardial infarction, the recommended management would be Dual antiplatelet therapy with primary PCI. This approach aligns with current clinical guidelines and has been demonstrated to lead to successful revascularization, no recurrent events at 1 year, and return to normal activity.",
                "expected": "immediate reperfusion therapy, dual antiplatelet therapy, beta-blockers, ACE inhibitors, statin therapy",
                "reasoning_type": "treatment_planning",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "medreason_003",
                "score": 35.12499999999999,
                "correct": false,
                "metrics": {
                  "reasoning_quality": 0.5833333333333333,
                  "clinical_accuracy": 0.2033333333333333,
                  "diagnostic_process": 0.12,
                  "knowledge_integration": 0.32916666666666666,
                  "overall_score": 0.35124999999999995
                },
                "response": " Based on the pattern recognition of the administered drug (Furosemide, a loop diuretic), the primary clinical indications suggest Heart Failure, Edema, or Hypertension. Given that acute shortness of breath is a common symptom in heart failure, the most likely differential diagnoses for an elderly patient presenting with this symptom are:\n\n1. Heart Failure with Reduced Ejection Fraction (HFrEF) - This condition is characterized by symptoms such as dyspnea, fatigue, and peripheral edema. The primary therapeutic approach includes ACE inhibitors, beta-blockers, and diuretics to reduce mortality and improve symptoms.\n\n2. Acute Decompensated Heart Failure (ADHF) - This is a clinical syndrome resulting from the acute worsening of chronic heart failure or the development of new-onset heart failure in a patient with previously stable chronic heart failure. It is also characterized by symptoms such as dyspnea, fatigue, and peripheral edema, and the therapeutic approach involves rapid symptom relief using diuretics, along with other treatments like ACE inhibitors and beta-blockers.\n\n3. Pulmonary Edema - This condition is a potentially life-threatening accumulation of fluid in the air sacs (alveoli) of the lungs, usually due to left heart failure or lung disease. It can cause shortness of breath, coughing, and rapid breathing. In the case of an elderly patient with heart failure, this could be a complication.\n\n4. Pulmonary Embolism - This is a blockage in a pulmonary artery caused by a clot or other material that has traveled to the lung from another part of the body. Although not directly related to heart failure medications, it can coexist with heart failure and present with similar symptoms.\n\nThe confirmation tier involves cross-referencing multiple medical sources for hypothesis validation and providing detailed evidence synthesis and confidence assessment. For instance, a comprehensive review of clinical studies would support the effectiveness of ACE inhibitors, beta-blockers, and diuretics in reducing mortality and improving symptoms in HFrEF and ADHF patients.",
                "expected": "acute heart failure, pneumonia, COPD exacerbation, pulmonary embolism, pneumothorax",
                "reasoning_type": "differential_diagnosis",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "medreason_004",
                "score": 31.423148148148144,
                "correct": false,
                "metrics": {
                  "reasoning_quality": 0.3583333333333333,
                  "clinical_accuracy": 0.27999999999999997,
                  "diagnostic_process": 0.26666666666666666,
                  "knowledge_integration": 0.33564814814814814,
                  "overall_score": 0.31423148148148144
                },
                "response": " Type 2 Diabetes Mellitus (T2DM) is a metabolic disorder characterized by chronic hyperglycemia due to impaired insulin secretion and insulin resistance, which leads to an inability of the body to maintain normal glucose homeostasis.\n\nIn T2DM, the pancreas initially overcompensates by producing more insulin (hyperinsulinemia) to compensate for insulin resistance. Over time, this increased demand may lead to beta-cell exhaustion, resulting in reduced insulin production and secretion (functional beta-cell deficiency). This imbalance results in persistently high levels of blood glucose, which can lead to various long-term complications such as cardiovascular disease, neuropathy, and nephropathy.\n\nInsulin resistance is primarily caused by a combination of genetic, environmental, and lifestyle factors such as obesity, physical inactivity, and poor dietary habits. In addition, abnormalities in other hormones like ghrelin, leptin, adiponectin, and resistin contribute to insulin resistance.\n\nIn summary, the pathophysiology of T2DM involves a complex interplay between genetic, environmental, and lifestyle factors leading to impaired insulin secretion and insulin resistance, resulting in hyperglycemia and long-term complications. The first-line evidence-based treatment for T2DM is metformin-based therapy with lifestyle modifications, which helps reduce cardiovascular mortality and improve glycemic control.",
                "expected": "insulin resistance in peripheral tissues leading to compensatory hyperinsulinemia, eventual beta-cell dysfunction and relative insulin deficiency",
                "reasoning_type": "pathophysiology",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "medreason_005",
                "score": 27.19209090909091,
                "correct": false,
                "metrics": {
                  "reasoning_quality": 0.47500000000000003,
                  "clinical_accuracy": 0.08863636363636362,
                  "diagnostic_process": 0.12,
                  "knowledge_integration": 0.31329999999999997,
                  "overall_score": 0.2719209090909091
                },
                "response": " Based on the provided pattern recognition and hypothesis testing, the suspected condition is Acute Coronary Syndrome (ACS). As this is not a stroke, the following investigations would be appropriate for a patient with suspected ACS:\n\n1. Electrocardiogram (ECG) to assess cardiac rhythm and identify any signs of myocardial ischemia or infarction.\n2. Troponin I or T blood tests to detect cardiac muscle damage.\n3. D-dimer test to rule out deep vein thrombosis or pulmonary embolism as potential alternative diagnoses.\n4. Brain natriuretic peptide (BNP) or N-terminal pro BNP (NT-proBNP) to assess for congestive heart failure.\n5. Chest X-ray to evaluate the size and shape of the cardiac silhouette, as well as identify any pulmonary edema or consolidation.\n6. Echocardiogram to assess left ventricular function, wall motion abnormalities, and valvular abnormalities.\n7. Coronary angiography may be necessary for further evaluation and potential revascularization if indicated by the above tests.",
                "expected": "immediate CT brain, blood glucose, ECG, full blood count, coagulation studies, renal function",
                "reasoning_type": "investigation_planning",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              }
            ],
            "status": "completed"
          },
          "evaluation_time_seconds": 14.625449,
          "gpu_stats": {
            "allocated_gb": 0.26,
            "reserved_gb": 0.29,
            "total_gb": 23.64,
            "utilization_percent": 1.1
          }
        }
      },
      "end_time": "2025-06-20T04:54:33.765722"
    },
    "pubmedqa": {
      "benchmark_name": "pubmedqa",
      "start_time": "2025-06-20T04:54:33.769537",
      "models": {
        "hierarchical_system": {
          "results": {
            "model_name": "unknown_model",
            "benchmark_name": "PubMedQA",
            "evaluation_time": 10.97064995765686,
            "total_questions": 5,
            "successful_evaluations": 5,
            "metrics": {
              "total_questions": 5,
              "average_score": 40.0,
              "accuracy": 40.0,
              "correct_answers": 2,
              "benchmark_name": "PubMedQA"
            },
            "individual_results": [
              {
                "question_id": "pubmedqa_001",
                "predicted": "yes",
                "expected": "yes",
                "correct": true,
                "score": 100,
                "metrics": {
                  "accuracy": 1.0,
                  "confidence": 0.8999999999999999,
                  "evidence_quality": 0.39999999999999997
                },
                "response": " Based on the pattern recognition, hypothesis testing, and confirmation stages, it can be concluded that Metformin does indeed reduce cardiovascular risk in Type 2 Diabetes. This is supported by multiple lines of evidence including the UKPDS study showing a reduction in cardiovascular mortality by 30-40%, as well as numerous clinical success stories demonstrating significant reductions in cardiovascular events and improved glycemic control with Metformin-based therapy. The confidence in this diagnosis is high given the robust evidence base supporting the use of Metformin for Type 2 Diabetes management.",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "pubmedqa_002",
                "predicted": "no",
                "expected": "yes",
                "correct": false,
                "score": 0,
                "metrics": {
                  "accuracy": 0.0,
                  "confidence": 0.7499999999999999,
                  "evidence_quality": 0.39999999999999997
                },
                "response": " Based on the pattern recognition, hypothesis testing, and confirmation processes, it can be concluded that Atorvastatin is primarily used for the management of Hyperlipidemia, Primary CV Prevention, and Secondary CV Prevention. The drug works by reducing LDL cholesterol levels (by 30-50%) and significantly decreasing cardiovascular events and mortality risk.\n\nThe hypothesis testing process revealed that high-intensity statin therapy is the first-line evidence-based treatment for Hyperlipidemia, which aligns with multiple clinical success stories from various sources such as PROVE-IT and TNT trials. These studies demonstrate the efficacy of Atorvastatin in reducing LDL levels and preventing cardiovascular events in high-risk patients, supporting the primary therapeutic benefits of this medication.\n\nRegarding your question about the effectiveness of statins in primary prevention of cardiovascular disease, the evidence suggests that statins can help reduce the risk of cardiovascular events in individuals with elevated LDL cholesterol levels and no history of cardiovascular disease. However, it is essential to consider individual patient factors such as comorbidities, age, family history, lifestyle habits, and other medications before initiating treatment with statins for primary prevention purposes. Always consult a healthcare professional for personalized medical advice.",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "pubmedqa_003",
                "predicted": "no",
                "expected": "no",
                "correct": true,
                "score": 100,
                "metrics": {
                  "accuracy": 1.0,
                  "confidence": 0.7999999999999999,
                  "evidence_quality": 0.8
                },
                "response": " Based on the pattern recognition, hypothesis testing, and confirmation tiers:\n\nAtorvastatin (an HMG-CoA Reductase Inhibitor) is primarily indicated for Hyperlipidemia, Primary CV Prevention, and Secondary CV Prevention. The primary therapeutic benefit of Atorvastatin is reducing LDL cholesterol by 40-50%.\n\nIn the hypothesis testing tier, it was found that ACE inhibitors + Beta-blockers + Diuretics is the preferred first-line therapy for Heart Failure with Reduced Ejection Fraction based on robust clinical trial evidence demonstrating significant improvements in patients.\n\nHowever, the question at hand asks about vitamin E supplementation and its effect on heart disease prevention.\n\nIn terms of preventing heart disease, current evidence does not support the use of vitamin E supplementation. While some early studies suggested a potential protective effect, more recent, larger trials have failed to confirm this benefit. For example, the Heart Outcomes Prevention Evaluation (HOPE) study and the GISSI-Prevenzione trial did not find a significant reduction in major coronary events or total mortality with vitamin E supplementation.\n\nTherefore, based on current evidence, it is not recommended to use vitamin E supplementation as a preventive measure for heart disease. Always consult with a healthcare professional before starting any new medication or supplement regimen.",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "pubmedqa_004",
                "predicted": "yes",
                "expected": "maybe",
                "correct": false,
                "score": 0,
                "metrics": {
                  "accuracy": 0.0,
                  "confidence": 0.7,
                  "evidence_quality": 0.6
                },
                "response": " Based on the given information, Atorvastatin is a medication primarily used to manage Hyperlipidemia, Primary CV Prevention, and Secondary CV Prevention. The primary therapeutic benefit of Atorvastatin is reducing LDL cholesterol by 40-50%.\n\nIn the context of Acute Coronary Syndrome (ACS), dual antiplatelet therapy (Aspirin + P2Y12 inhibitor) is the preferred first-line therapy, supported by robust clinical trial evidence.\n\nHowever, the question about the beneficial use of aspirin for primary prevention in elderly patients requires a separate analysis. According to the American College of Cardiology/American Heart Association (ACC/AHA) guideline on the prevention of cardiovascular disease, aspirin may be considered for primary prevention in elderly patients with a high risk of developing cardiovascular events, but the decision should be individualized based on the patient's overall health status, bleeding risk, and life expectancy. It is essential to consult the latest guidelines and consider each patient's unique clinical scenario before making recommendations regarding aspirin use for primary prevention in elderly patients.",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "pubmedqa_005",
                "predicted": "maybe",
                "expected": "yes",
                "correct": false,
                "score": 0,
                "metrics": {
                  "accuracy": 0.0,
                  "confidence": 0.7999999999999999,
                  "evidence_quality": 0.19999999999999998
                },
                "response": " Based on the pattern recognition of Lisinopril (an ACE inhibitor) being prescribed for various conditions including Heart Failure, Hypertension, Post-MI, and Diabetic Nephropathy, it is reasonable to suspect that the patient may be suffering from one or more of these conditions.\n\nIn the hypothesis testing phase, we cross-referenced multiple medical sources such as SOLVD, MERIT-HF, CIBIS-II, and ACC/AHA guidelines which all support the use of ACE inhibitors + Beta-blockers + Diuretics as the preferred first-line therapy for Heart Failure with Reduced Ejection Fraction. This strongly suggests that the patient's primary diagnosis could be Heart Failure with Reduced Ejection Fraction.\n\nIn the confirmation phase, we integrated all available information from clinical success stories demonstrating improved survival rates, reduced hospitalizations, and improved NYHA class in patients receiving this guideline-directed medical therapy. This provides robust evidence that ACE inhibitors do indeed reduce mortality in heart failure, thereby confirming our diagnosis.\n\nFinal Diagnostic Response: Given the pattern recognition, hypothesis testing, and confirmation stages, it is highly likely that the patient is suffering from Heart Failure with Reduced Ejection Fraction. The prescribed Lisinopril (an ACE inhibitor) aligns with this diagnosis, and the supportive clinical evidence reinforces this conclusion. It is essential to monitor the patient closely and adjust therapy as necessary based on response and any adverse effects.",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              }
            ],
            "status": "completed"
          },
          "evaluation_time_seconds": 10.974252,
          "gpu_stats": {
            "allocated_gb": 0.26,
            "reserved_gb": 0.29,
            "total_gb": 23.64,
            "utilization_percent": 1.1
          }
        }
      },
      "end_time": "2025-06-20T04:54:44.949934"
    },
    "msmarco": {
      "benchmark_name": "msmarco",
      "start_time": "2025-06-20T04:54:44.952981",
      "models": {
        "hierarchical_system": {
          "results": {
            "model_name": "unknown_model",
            "benchmark_name": "MSMARCO",
            "evaluation_time": 27.917960166931152,
            "total_questions": 10,
            "successful_evaluations": 10,
            "metrics": {
              "total_questions": 10,
              "average_score": 58.66349206349206,
              "accuracy": 60.0,
              "correct_answers": 6,
              "benchmark_name": "MSMARCO"
            },
            "individual_results": [
              {
                "question_id": "msmarco_001",
                "score": 60.57142857142858,
                "correct": true,
                "metrics": {
                  "retrieval_score": 0.14285714285714285,
                  "answer_score": 0.8714285714285714,
                  "medical_relevance": 1.0,
                  "overall_score": 0.6057142857142858,
                  "retrieved_docs_count": 10
                },
                "response": " The symptoms of Type 2 Diabetes Mellitus may include:\n\n1. Frequent urination: Excess sugar in the blood leads to an increased production of urine.\n\n2. Increased thirst and hunger: As the body tries to flush out excess sugar through urination, it becomes dehydrated, leading to increased thirst. Additionally, the body may not be able to use glucose for energy effectively, resulting in increased appetite.\n\n3. Fatigue: Due to the body's inability to convert glucose into energy, a person with diabetes may experience fatigue and low energy levels.\n\n4. Blurred vision: High blood sugar can affect the focusing lens of the eye, leading to blurred vision.\n\n5. Slow-healing wounds or frequent infections: Diabetes impairs the immune system and affects circulation, making it harder for wounds to heal and increasing the risk of infections.\n\n6. Numbness or tingling in the hands or feet: This is caused by nerve damage due to high blood sugar levels.\n\nIn addition to these symptoms, individuals with Type 2 Diabetes may also experience weight gain, especially around the waist, and increased feelings of hunger even after eating. It's important to note that some individuals may not exhibit any symptoms at all, making regular screenings crucial for early detection and management.\n\nFor a more detailed explanation or if you have specific questions about diabetes and its treatment, please consult a healthcare professional.",
                "expected": "increased thirst, frequent urination, fatigue, blurred vision",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "msmarco_002",
                "score": 73.66666666666666,
                "correct": true,
                "metrics": {
                  "retrieval_score": 0.375,
                  "answer_score": 0.9666666666666666,
                  "medical_relevance": 1.0,
                  "overall_score": 0.7366666666666666,
                  "retrieved_docs_count": 10
                },
                "response": " Hypertension, also known as high blood pressure, is primarily diagnosed based on the average measurement of systolic and diastolic blood pressures during multiple visits. The American Heart Association (AHA) and the American College of Cardiology (ACC) define hypertension as a systolic blood pressure consistently above 130 mmHg or a diastolic blood pressure consistently above 80 mmHg.\n\nThe diagnosis process includes:\n\n1. Obtaining a medical history to identify potential risk factors and other health conditions that may be related to hypertension.\n2. Performing a physical examination to evaluate for signs of target organ damage, such as cardiovascular disease or renal dysfunction.\n3. Measuring blood pressure on at least two occasions, in both arms, using appropriate equipment, with the patient in a seated position after a 5-minute rest. Ambulatory monitoring or home blood pressure measurements may also be used to confirm the diagnosis.",
                "expected": "blood pressure measurements over multiple visits",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "msmarco_003",
                "score": 85.00000000000001,
                "correct": true,
                "metrics": {
                  "retrieval_score": 0.625,
                  "answer_score": 1.0,
                  "medical_relevance": 1.0,
                  "overall_score": 0.8500000000000001,
                  "retrieved_docs_count": 10
                },
                "response": " The primary medication used to treat Heart Failure is a combination of ACE Inhibitors (such as Lisinopril), Beta-blockers, and Diuretics. This therapy is referred to as Guideline-directed medical therapy and is supported by robust clinical trial evidence demonstrating significant improvements in patient outcomes. Examples of such improvements include improved survival rates, reduced hospitalizations, and improved quality of life.\n\nHere's a summary of the hierarchical diagnostic reasoning process:\n\nTIER 1 - PATTERN RECOGNITION:\n- Identified pattern: Lisinopril (ACE Inhibitor)\n\nTIER 2 - HYPOTHESIS TESTING:\n- Hypothesis: ACE inhibitors + Beta-blockers + Diuretics is the preferred first-line therapy for Heart Failure with Reduced Ejection Fraction based on robust clinical trial evidence.\n\nTIER 3 - CONFIRMATION:\n- Evidence: Clinical success stories demonstrating improved survival, reduced hospitalizations, and improved quality of life in patients with Heart Failure treated with the recommended guideline-directed medical therapy (ACE-I + Beta-blocker + Diuretic).",
                "expected": "ACE inhibitors, beta-blockers, diuretics",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "msmarco_004",
                "score": 47.66666666666667,
                "correct": false,
                "metrics": {
                  "retrieval_score": 0.3,
                  "answer_score": 0.4666666666666667,
                  "medical_relevance": 0.85,
                  "overall_score": 0.4766666666666667,
                  "retrieved_docs_count": 10
                },
                "response": " Based on the pattern recognition of the drug Atorvastatin (HMG-CoA Reductase Inhibitor) being prescribed, the primary therapeutic benefit of which is reducing LDL cholesterol, and the hypothesis testing and confirmation that dual antiplatelet therapy (Aspirin + P2Y12 inhibitor) is a first-line evidence-based treatment for Acute Coronary Syndrome (ACS), it is highly likely that the cause of myocardial infarction in this case could be ACS. The recurrent use of dual antiplatelet therapy has been shown to significantly reduce recurrent myocardial infarctions and improve outcomes for patients with ACS. However, it's important to note that other conditions can also cause myocardial infarction, and a thorough diagnostic workup should be conducted to rule out other possible causes. Always consult the latest clinical guidelines and evidence-based resources to ensure accurate and up-to-date information is being used in patient care.",
                "expected": "coronary artery blockage from atherosclerotic plaque",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "msmarco_005",
                "score": 45.714285714285715,
                "correct": false,
                "metrics": {
                  "retrieval_score": 0.14285714285714285,
                  "answer_score": 0.5,
                  "medical_relevance": 1.0,
                  "overall_score": 0.4571428571428572,
                  "retrieved_docs_count": 10
                },
                "response": " The treatment of pneumonia depends on the causative agent and the severity of the infection. Here are some common treatments based on clinical guidelines:\n\n1. Bacterial Pneumonia:\n   - First-line antibiotics: Macrolides (e.g., azithromycin), fluoroquinolones (e.g., levofloxacin) or beta-lactams (e.g., amoxicillin/clavulanate). The choice of antibiotic depends on the local prevalence of resistant bacteria.\n   - Supportive therapy: Oxygen, hydration, and analgesics for pain relief.\n\n2. Viral Pneumonia (e.g., caused by influenza or SARS-CoV-2):\n   - Antiviral medications may be used, such as oseltamivir for influenza or remdesivir for SARS-CoV-2 (in hospitalized patients).\n   - Supportive therapy: As with bacterial pneumonia, oxygen, hydration, and analgesics are important.\n\n3. Community-acquired pneumonia (CAP):\n   - Initial empirical antibiotic treatment for CAP should include coverage against Streptococcus pneumoniae, Haemophilus influenzae, and atypical pathogens like Mycoplasma pneumoniae or Legionella pneumophila. Common choices are macrolides (e.g., azithromycin), fluoroquinolones (e.g., levofloxacin) or doxycycline.\n   - If the patient's condition deteriorates or there is a high suspicion of resistant bacteria, consider adding vancomycin or linezolid.\n\n4. Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP):\n   - Initial treatment for HAP/VAP should include coverage against gram-negative bacilli (e.g., Pseudomonas aeruginosa), Staphylococcus aureus, and anaerobes. Common choices are piperacillin/tazobactam, ceftriaxone, or meropenem.\n   - For suspected Pseudomonas aeruginosa infections, consider adding amikacin, ciprofloxacin, or tobramycin.",
                "expected": "antibiotics, supportive care, oxygen therapy",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "msmarco_006",
                "score": 37.66666666666667,
                "correct": false,
                "metrics": {
                  "retrieval_score": 0.25,
                  "answer_score": 0.5,
                  "medical_relevance": 0.3833333333333333,
                  "overall_score": 0.3766666666666667,
                  "retrieved_docs_count": 10
                },
                "response": " Risk factors for stroke include:\n\n1. Hypertension (High Blood Pressure): Chronic high blood pressure is a major cause of stroke, damaging the arteries that supply blood to the brain over time and leading to their narrowing or hardening.\n\n2. Age: The risk of stroke increases with age. While strokes can occur at any age, 55 years and older is considered high-risk.\n\n3. Family History: If a close relative (parent, sibling, or offspring) has had a stroke, you may be at greater risk.\n\n4. Diabetes Mellitus: People with diabetes have a higher risk of both ischemic and hemorrhagic strokes due to damage caused by prolonged high blood glucose levels.\n\n5. High Cholesterol Levels (Hyperlipidemia): High cholesterol contributes to the buildup of plaque in the arteries, which can lead to stroke.\n\n6. Smoking: Smokers have a higher risk of ischemic and hemorrhagic strokes due to damage to blood vessels from the toxic chemicals in tobacco smoke.\n\n7. Obesity: Being overweight or obese increases the risk of developing other stroke risk factors, such as high blood pressure and diabetes.\n\n8. Physical Inactivity: Lack of regular exercise can lead to conditions like hypertension and diabetes, increasing the risk of stroke.\n\n9. Alcohol Consumption: Heavy alcohol consumption can damage the brain and contribute to high blood pressure, an irregular heartbeat, and other factors that increase stroke risk.\n\n10. Poor Diet: Consuming a diet low in fruits, vegetables, and whole grains while high in saturated fats and sodium can lead to conditions like hypertension and diabetes, increasing the risk of stroke.",
                "expected": "hypertension, diabetes, smoking, atrial fibrillation",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "msmarco_007",
                "score": 56.761904761904766,
                "correct": true,
                "metrics": {
                  "retrieval_score": 0.2857142857142857,
                  "answer_score": 0.6333333333333333,
                  "medical_relevance": 1.0,
                  "overall_score": 0.5676190476190477,
                  "retrieved_docs_count": 10
                },
                "response": " The diagnosis of asthma follows a three-tier reasoning process:\n\nTIER 1 - PATTERN RECOGNITION:\n- Identify relevant medical patterns and generate initial differential diagnoses.\n- Focus on rapid pattern recognition and clinical intuition.\n- Use the comprehensive knowledge base for pattern matching.\n\nPattern 1: Clinical Presentation:\n- Recurrent wheezing, chest tightness, shortness of breath, and coughing, particularly at night or in response to cold air, exercise, or allergens.\n- Variability in lung function and reversibility of bronchoconstriction with bronchodilator therapy.\n- A history of atopy (allergic rhinitis, eczema) or a personal or family history of asthma.\n\nPattern 2: Spirometry:\n- Obstructive spirometric pattern with FEV1/FVC ratio <0.7 and bronchodilator reversibility >12% and >200 mL.\n- Provocative testing, such as methacholine challenge or exercise challenge, can help confirm the diagnosis.\n\nTIER 2 - HYPOTHESIS TESTING:\n- Test hypotheses using evidence-based reasoning chains.\n- Apply systematic diagnostic reasoning and knowledge graph connections.\n- Cross-reference multiple medical sources for hypothesis validation.\n\nHypothesis 1: Clinical Condition: Asthma\n\nDIAGNOSTIC CRITERIA:\n- Recurrent wheezing, chest tightness, shortness of breath, and coughing.\n- Variability in lung function and reversibility of bronchoconstriction with bronchodilator therapy.\n- A history of atopy or a personal or family history of asthma.\n\nProven Clinical Benefits:\n- Improved symptom control and quality of life with inhaled corticosteroids, long-acting beta2-agonists, and leukotriene modifiers.\n- Reduced risk of exacerbations and emergency department visits with controller medications and action plans.\n\nTIER 3 - CONFIRMATION:\n- Confirm diagnosis with comprehensive clinical evidence.\n- Integrate all available information for final diagnostic confirmation.\n- Provide detailed evidence synthesis and confidence assessment.\n\nEvidence 1: Key Learning Points:\n- Accurate asthma diagnosis is crucial for effective management and improved outcomes.\n- Diagnostic tests should be tailored to the individual patient and their clinical presentation.\n- Collaborative care with primary care providers, specialists, and patients is essential for optimal asthma management.",
                "expected": "spirometry, peak flow measurement, clinical history",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "msmarco_008",
                "score": 42.00000000000001,
                "correct": false,
                "metrics": {
                  "retrieval_score": 0.125,
                  "answer_score": 0.5,
                  "medical_relevance": 0.85,
                  "overall_score": 0.42000000000000004,
                  "retrieved_docs_count": 10
                },
                "response": " Based on the pattern recognition, hypothesis testing, and confirmation processes performed, it has been determined that the patient may have Type 2 Diabetes Mellitus. This diagnosis is supported by the repeated identification of Metformin as a first-line evidence-based treatment for Type 2 Diabetes Mellitus, which reduces hepatic glucose production and improves insulin sensitivity.\n\nIn addition to the primary clinical indications of Type 2 Diabetes Mellitus, there are several potential complications associated with this condition that should be closely monitored:\n\n1. Cardiovascular Disease: People with Type 2 Diabetes have a higher risk for various cardiovascular problems, including coronary artery disease, heart attack, stroke, and narrowing of arteries (atherosclerosis).\n\n2. Nephropathy (Kidney Disease): High blood sugar levels can cause changes in the blood vessels in the kidneys and potentially lead to kidney damage or kidney failure.\n\n3. Neuropathy (Nerve Damage): High blood sugar levels can cause a variety of nerve problems, including numbness, tingling, pain, or weakness in the hands and feet.\n\n4. Retinopathy (Eye Disease): Diabetes can damage the blood vessels in the retina, potentially leading to blindness.\n\n5. Foot Complications: Nerve damage and poor circulation can lead to foot ulcers and infections, which may require amputation in severe cases.\n\n6. Hearing Impairment or other auditory problems.\n\n7. Skin Conditions: Diabetes may increase the risk of skin infections and other complications.\n\nIt is essential to monitor for these potential complications and manage them appropriately to ensure the best possible health outcomes for the patient. In this case, the treatment of Type 2 Diabetes Mellitus with Metformin can help reduce cardiovascular mortality by 30-40% and potentially delay or prevent some of these complications.",
                "expected": "nephropathy, retinopathy, neuropathy, cardiovascular disease",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "msmarco_009",
                "score": 66.92063492063491,
                "correct": true,
                "metrics": {
                  "retrieval_score": 0.4444444444444444,
                  "answer_score": 0.7285714285714285,
                  "medical_relevance": 1.0,
                  "overall_score": 0.6692063492063491,
                  "retrieved_docs_count": 10
                },
                "response": " Metformin is a medication primarily used for the treatment of Type 2 Diabetes Mellitus. It works by reducing hepatic glucose production and improving insulin sensitivity, thereby helping to control blood sugar levels. This mechanism of action makes it an effective tool in managing Type 2 diabetes.\n\nOne of the significant clinical benefits associated with metformin is a reduction in cardiovascular mortality by 30-40%, as demonstrated in studies like the UKPDS (United Kingdom Prospective Diabetes Study). This reduced risk is due to the decreased incidence of myocardial infarction (heart attack) and other cardiovascular events.\n\nThe evidence for metformin's efficacy can be seen in numerous clinical success stories, where patients with Type 2 diabetes and a high risk of cardiovascular disease have experienced significant reductions in cardiovascular events, such as myocardial infarction (MI), alongside improved glycemic control. For instance, an individual might start with an HbA1c level of 8.2% (indicating poor glycemic control) and, after metformin-based therapy and lifestyle modifications, see their HbA1c level drop to 6.8%, indicating better control over their diabetes.\n\nIn summary, metformin is an evidence-based therapy with proven clinical benefits for the management of Type 2 Diabetes Mellitus, particularly in reducing cardiovascular mortality and improving glycemic control. It works by decreasing hepatic glucose production and enhancing insulin sensitivity.",
                "expected": "reduces hepatic glucose production, improves insulin sensitivity",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              },
              {
                "question_id": "msmarco_010",
                "score": 70.66666666666666,
                "correct": true,
                "metrics": {
                  "retrieval_score": 0.3,
                  "answer_score": 0.9666666666666666,
                  "medical_relevance": 1.0,
                  "overall_score": 0.7066666666666666,
                  "retrieved_docs_count": 10
                },
                "response": " Signs of a heart attack can vary greatly among individuals, but here are some common symptoms to look out for:\n\n1. Chest discomfort: Most heart attacks involve discomfort in the center of the chest that lasts more than a few minutes, or it may go away and come back. It can feel like uncomfortable pressure, squeezing, fullness, or pain.\n\n2. Discomfort in other areas of the upper body: Symptoms can include pain or discomfort in one or both arms, the back, neck, jaw, or stomach.\n\n3. Shortness of breath: This may occur during rest or during physical exertion, and it can feel like you're choking, can't catch your breath, or are lightheaded.\n\n4. Cold sweat: Clammy skin and cold sweats can be a sign of a heart attack.\n\n5. Nausea, lightheadedness, or dizziness: These symptoms might suggest that the blood supply to the heart is being interrupted.\n\n6. Unexplained fatigue: If you feel unusually tired for no apparent reason, it could potentially be a sign of a heart attack, especially if accompanied by other symptoms.\n\nIf you or someone else experiences these symptoms, it's crucial to seek immediate medical attention as a heart attack is a medical emergency that requires prompt treatment. Call your local emergency number right away if you suspect a heart attack.",
                "expected": "chest pain, shortness of breath, nausea, sweating",
                "model_name": "unknown_model",
                "retrieved_docs_count": 10
              }
            ],
            "status": "completed"
          },
          "evaluation_time_seconds": 27.923042,
          "gpu_stats": {
            "allocated_gb": 0.26,
            "reserved_gb": 0.29,
            "total_gb": 23.64,
            "utilization_percent": 1.1
          }
        }
      },
      "end_time": "2025-06-20T04:55:13.082980"
    }
  }
}